Table 2.
Characteristics of 20 hematology patients with COVID‐19
| Patient | Sex | Age on admission (years) | Length of admission (days) | Alive/deceased | COVID‐19 symptom score | Hematological disease | Cancer treatment | Clinical features | SARS‐CoV‐2 Swab PCR | Finds on chest X‐ray | Serology for anti‐SARS‐CoV‐2 IgG | Time between Symptom onset and PCR sample (days) | Time between symptom onset and serum sample (days) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 89 | 12 | Alive | 6 | Myeloma | Lenalidomide and dexamethasone | SOB, cough, and fever | Positive | Patchy opacification of lower zones bilaterally | Negative | 11 | 11 |
| 2 | F | 86 | 6 | Deceased | 7 | Myeloma | Lenalidomide and dexamethasone | Asymptomatic | Positive | Linear atelectasis in both lowers but no focal consolidation | Negative | 0 | 18 |
| 3 | M | 70 | 3 | Alive | 6 | Lymphoma | Tirabutinib | Fever, cough, and SOB | Positive | Extensive peripheral subpleural ground‐glass opacities with consolidation | Negative | 8 | 8 |
| 4 | M | 79 | 4 | Alive | 3 | Lymphoma | Unknown | Asymptomatic | Positive | No lung parenchymal changes of COVID‐19 | Negative | 0 | 25 |
| 5 | M | 87 | 14 | Alive | 3 | Myeloma | Lenalidomide and dexamethasone | Asymptomatic | Positive | Bilateral peripheral ground‐glass opacities | Negative | 0 | 12 |
| 6 | M | 82 | 39 | Alive | 2 | Myeloma | Lenalidomide and dexamethasone | Fever | Positive | No convincing features to suggest COVID‐19 | Negative | 7 | 30 |
| 7 | M | 56 | 13 | Alive | 4 | Leukemia | Unknown | Fever and SOB | Positive | Unilateral consolidation | Positive | 6 | 19 |
| 8 | M | 74 | 27 | Alive | 4 | Leukemia | Cyatarbine venetoclax | Fever | Positive | Right side pleural effusion | Negative | 6 | 8 |
| 9 | M | 93 | 19 | Alive | 1 | Lymphoma | Unknown | Asymptomatic | Positive | No CXR results | Positive | 6 | 13 |
| 10 | M | 63 | 6 | Alive | 2 | Lymphoma | Pomalidomide, dexamethasone, and apixaban | Asymptomatic | Positive | Bilateral lower lobe pulmonary embolism | Not tested | 0 | – |
| 11 | M | 69 | 14 | Alive | 4 | Leukemia | Lenalidomide, dexamethasone, and daratumumab | Fever | Positive | Right‐side pleural effusion | Negative | 6 | 7 |
| 12 | M | 79 | 8 | Deceased | 7 | Myeloma | Pomalidomide and dexamethasone | Fever and SOB | Positive | No CXR results | Not tested | 0 | – |
| 13 | M | 77 | 5 | Alive | 3 | Lymphoma | Dexamethasone | Cough and SOB | Positive | No CXR results | Negative | 0 | 0 |
| 14 | M | 60 | 8 | Deceased | 9 | Leukemia | Not on treatment | Fever, cough, and SOB | Positive | Coarsened airspace shadowing in both lungs | Not tested | 0 | – |
| 15 | F | 86 | 8 | Deceased | 8 | Leukemia | Not on treatment | Abdominal pain | Positive | Left basal apical linear atelectasis | Not tested | 1 | – |
| 16 | F | 92 | 18 | Alive | 3 | Leukemia | Mycophenolate and prednisolone | Asymptomatic | Positive | Patchy bibasal consolidation | Not tested | 0 | – |
| 17 | M | 88 | 0 | Deceased | 8 | Leukemia | Radiotherapy | SOB | Positive | Patchy bilateral perihilar inflammatory changes | Not tested | 1 | – |
| 18 | F | 68 | 43 | Deceased | 8 | Lymphoma | Not on treatment | SOB | Positive | Bilateral patchy air space opacification | Not tested | 0 | – |
| 19 | F | 85 | 0 | Deceased | 9 | Lymphoma | Not on treatment | Fever and abdominal pain | Positive | Bibasal consolidation with bilateral pleural effusions | Not tested | 24 | – |
| 20 | M | 61 | 5 | Alive | 5 | Lymphoma | Atorvastatin | Fever, cough, and SOB | Positive | Bilateral air space shadowing | Negative | 0 | 2 |
Abbreviations: CXR, chest X‐ray; F, female; M, male; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; SOB, shortness of breath.